- Atogepant met primary endpoint for all doses and dose regimens
- Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over... read more
Genentech, announced on 6/8/2018 that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a... read more
Magenta Therapeutics announced on 6/8/2018 that it has launched an initial public offering of its common stock. Magenta is offering 6,666,667 shares of its common stock, subject to market and... read more
Lundbeck A/S (Lundbeck) announced on 6/6/2018 that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ) investigation related to... read more
Pfizer Inc. (NYSE:PFE) announced on 6/7/2018 that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for... read more